Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 05 Apr 2022
CADTH Strategy 2022-2025: anticipate, innovate and transform
5 April 2022 - CADTH is pleased to share Ahead of the Curve: Shaping Future-Ready Heath Systems, the agency's new ...
Posted by Michael Wonder on 05 Apr 2022
Curium announces FDA approval of a generic version of DaTscan (Ioflupane I 123 injection) in the U.S.
5 April 2022 - Curium announced today that its generic version of DaTscan (Ioflupane I 123 injection) was approved on 30 ...
Posted by Michael Wonder on 05 Apr 2022
FDA updates sotrovimab emergency use authorisation
5 April 2022 - Sotrovimab is no longer authorised to treat COVID-19 in any U.S. region due to increases in ...
Posted by Michael Wonder on 05 Apr 2022
Rights watchdog urges quick reimbursement of expensive new drugs
5 April 2022 - The National Human Rights Commission of Korea welcomed the recent reimbursement of CAR-T cell therapy Kymriah ...
Posted by Michael Wonder on 05 Apr 2022
Watchdog urged to probe McKinsey over work with FDA, opioid manufacturers
5 April 2022 - The consulting firm was getting paid by opioid makers while working for the FDA. ...
Posted by Michael Wonder on 05 Apr 2022
Consultation now open - review of base case discount rate at 3A.1 of the PBAC Guidelines
5 April 2022 - The Commonwealth has entered into a new Strategic Agreement in relation to reimbursement, health technology assessment ...
Posted by Michael Wonder on 05 Apr 2022
Janssen announces Health Canada approval of Rybrevant (amivantamab), the first and only targeted treatment for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations
4 April 2022 - Targeting both cancer driving and resistance mechanism pathways, Rybrevant offers a unique treatment approach for an ...
Posted by Michael Wonder on 05 Apr 2022
European Commission approves Kimmtrak (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
4 April 2022 - Kimmtrak demonstrated statistically and clinically meaningful overall survival benefit, hazard ratio of 0.51, with median overall ...
Posted by Michael Wonder on 04 Apr 2022
Locally made medicines
4 April 2022 - The Morrison Government is supporting new local jobs in Australia’s innovative medical sector and investing to secure ...
Posted by Michael Wonder on 04 Apr 2022
FDA shuts out its own experts in authorising another vaccine booster
3 April 2022 - Decisions like this only reinforce the perception that Covid policy is driven by groupthink and politics. ...
Posted by Michael Wonder on 04 Apr 2022
Upper Hutt dad's plea to PHARMAC to cover family's $5,200 a year bill for 'life changing' diabetes devices
2 April 2022 - A Kiwi teacher is calling for public funding for "life changing" diabetes devices after being forced ...
Posted by Michael Wonder on 04 Apr 2022
Novartis announces European Commission approval of Beovu for people living with diabetic macular oedema
31 March 2022 - Approval is based on year one data from the Phase 3 KESTREL and KITE trials investigating Beovu ...
Posted by Michael Wonder on 04 Apr 2022
Digital Medicine Society launches toolkit to support reimbursement for new drugs developed using digital outcomes
4 April 2022 - New essential resources ensure that patients will benefit without delay following regulatory acceptance of digital outcomes. ...
Posted by Michael Wonder on 04 Apr 2022
Mystery solved over Hansard change to hide budget’s missing $10 drug price cut
4 April 2022 - Financial Services Minister Jane Hume’s office asked Hansard staff to delete references to a planned $10 ...
Posted by Michael Wonder on 04 Apr 2022
Precigen receives fast track designation for PRGN-3006 UltraCAR-T in patients with relapsed or refractory acute myeloid leukaemia
4 April 2022 - PRGN-3006 UltraCAR-T previously received orphan drug designation in patients with acute myeloid leukaemia by the US FDA. ...